Clinical trial

Japanese BAY88-8223 Monotherapy Phase II Study

NCT01929655

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-09-30

PhasePHASE2

Study timeline

Study start (actual)2013-09-30Date precision: day

Registry last updated2018-04-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostatic Neoplasmsunresolved

Interventions

Radium-223 dichloride (Xofigo, BAY88-8223)DRUG

Sponsors & collaborators

Bayerlead sponsor

Mapped research locations

SapporoHokkaido, Japan2 FukuokaJapan1 YokohamaKanagawa, Japan1 ChibaJapan1 OkayamaJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01929655 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.